Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.

a Drug Development Department, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France b Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France c Department of Nuclear Medicine, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France d Merck and Co., Inc., Rahway, NJ, USA e Merck and Co., Inc., North Wales, PA, USA f Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France g INSERM U1030, Molecular Radiotherapy, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France h Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France